Abatacept in the Treatment of Active Psoriatic Arthritis: 24-Week Results from a Phase III Study

被引：0
|
作者：
Mease, P. [1 ,2 ]
Gottlieb, A. B. [3 ]
van der Heijde, D. [4 ]
FitzGerald, Oliver [5 ,6 ]
Johnsen, A. [7 ]
Nys, M. [8 ]
Banerjee, S. [7 ]
Gladman, D. [9 ,10 ]
机构：
[1] Swedish Med Ctr, Seattle, WA USA
[2] Univ Washington, Seattle, WA 98195 USA
[3] Tufts Univ, Sch Med, Boston, MA 02111 USA
[4] Leiden Univ, Med Ctr, Leiden, Netherlands
[5] St Vincents Univ Hosp, Dept Rheumatol, Dublin, Ireland
[6] Univ Coll Dublin, Dublin, Ireland
[7] Bristol Myers Squibb, Princeton, NJ USA
[8] Bristol Myers Squibb, Braine Lalleud, Belgium
[9] Univ Toronto, Rheumatol, Toronto, ON, Canada
[10] Toronto Western Hosp, Toronto, ON, Canada
来源：
ARTHRITIS & RHEUMATOLOGY | 2016年 / 68卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1041
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Abatacept in the Treatment of Active Psoriatic Arthritis: 24-Week Results from a Phase III Study
    Mease, Philip
    Gottlieb, Alice
    van der Heijde, Desiree
    FitzGerald, Oliver
    Johnsen, Alyssa
    Nys, Marleen
    Banerjee, Subhashis
    Gladman, Dafna
    [J]. JOURNAL OF RHEUMATOLOGY, 2017, 44 (06) : 926 - 926
  • [2] ABATACEPT IN THE TREATMENT OF ACTIVE PSORIATIC ARTHRITIS: 24-WEEK RESULTS FROM A PHASE III STUDY
    Mease, P.
    Gottlieb, A.
    Van der Heijde, D.
    Fitzgerald, O.
    Johnsen, A.
    Nys, M.
    Banerjee, S.
    Xinos, C.
    Gladman, D.
    [J]. INTERNAL MEDICINE JOURNAL, 2017, 47 : 23 - 23
  • [3] Adalimumab in psoriatic arthritis: 24-week results of a phase III study
    Mease, P
    Gladman, D
    Ritchlin, C
    Weinberg, M
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2005, 52 (03) : P2 - P2
  • [4] Adalimumab therapy in patients with psoriatic arthritis: 24-week results of a phase III study
    Mease, PJ
    Gladman, DD
    Ritchlin, CT
    Ruderman, EM
    Steinfeld, SED
    Choy, EHS
    Perdok, RJ
    Weinberg, TA
    [J]. ARTHRITIS AND RHEUMATISM, 2004, 50 (12): : 4097 - 4097
  • [5] ABATACEPT IN THE TREATMENT OF ACTIVE PSORIATIC ARTHRITIS: 1-YEAR RESULTS FROM A PHASE III STUDY
    Mease, P.
    Gottlieb, A.
    van der Heijde, D.
    FitzGerald, O.
    Johnsen, A.
    Nys, M.
    Banerjee, S.
    Gladman, D.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 145 - 146
  • [6] TOWARDS DEVELOPMENT OF AN ULTRASOUND ENTHESITIS SCORE IN PSORIATIC ARTHRITIS: 24-WEEK RESULTS FROM THE PHASE III RANDOMISED ULTIMATE STUDY
    D'agostino, M. A.
    Conaghan, P. G.
    Gaillez, C.
    Boers, M.
    Naredo, E.
    Carron, P.
    Hanova, P.
    Cazenave, T.
    Bakewell, C.
    Duggan, A. M.
    Goyanka, P.
    Schett, G.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 136 - 137
  • [7] Brodalumab in psoriatic arthritis (PsA): 24-week results from the phase III AMVISON-1 and-2 trials
    McInnes, Iain
    Mease, Philip
    Hjuler, Kasper Fjellhaugen
    Raymond, Kyle
    Helliwell, Philip
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB28 - AB28
  • [8] TOWARDS DEVELOPMENT OF AN ULTRASOUND ENTHESITIS SCORE IN PSORIATIC ARTHRITIS: 24-WEEK RESULTS FROM THE ULTIMATE STUDY
    D'Agostino, M. A.
    Conaghan, P. G.
    Gaillez, C.
    Boers, M.
    Naredo, E.
    Carron, P.
    Hanova, P.
    Cazenave, T.
    Bakewell, C.
    Duggan, A. M.
    Goyanka, P.
    Schett, G.
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2021, 39 (05) : 1160 - 1161
  • [9] Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study
    Song, I-H
    Heldmann, F.
    Rudwaleit, M.
    Haibel, H.
    Weiss, A.
    Braun, J.
    Sieper, J.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2011, 70 (06) : 1108 - 1110
  • [10] Efficacy and Safety of Neihulizumab (AbGn-168H) in Patients with Active Psoriatic Arthritis: 24-week Results from a Phase II Open Label Study
    Cohen, Stanley
    Fiechtner, Justus
    Mease, Philip
    Kaine, Jeffrey
    Kavanaugh, Arthur
    Cheng, Yi-Lin
    Chou, Claire
    Cheng, Ting-Ying
    Lin, Shih-Yao
    Genovese, Mark
    [J]. ARTHRITIS & RHEUMATOLOGY, 2020, 72
12345